Rosiglitazone ameliorates diffuse axonal injury by reducing loss of tau and up-regulating caveolin-1 expression
Rosiglitazone up-regulates caveolin-1 levels and has neuroprotective effects in both chronic and acute brain injury. Therefore, we postulated that rosiglitazone may ameliorate diffuse axonal injury via its ability to up-regulate caveolin-1, inhibit expression of amyloid-beta precursor protein, and r...
Main Authors: | Yong-lin Zhao, Jin-ning Song, Xu-dong Ma, Bin-fei Zhang, Dan-dong Li, Hong-gang Pang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
Series: | Neural Regeneration Research |
Subjects: | |
Online Access: | http://www.nrronline.org/article.asp?issn=1673-5374;year=2016;volume=11;issue=6;spage=944;epage=950;aulast=Zhao |
Similar Items
-
Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells
by: Seung-Yong Yoon, et al.
Published: (2010-11-01) -
Relevance of Phosphorylation and Truncation of Tau to the Etiopathogenesis of Alzheimer’s Disease
by: Yan Zhou, et al.
Published: (2018-02-01) -
Pathological Tau From Alzheimer’s Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau in vivo
by: Jin Miao, et al.
Published: (2019-03-01) -
Changes in microtubule-associated protein tau during peripheral nerve injury and regeneration
by: Guang-bin Zha, et al.
Published: (2016-01-01) -
Targeting Tau to Treat Clinical Features of Huntington's Disease
by: Maria Masnata, et al.
Published: (2020-11-01)